CT Lung Measurements Linked to Fibrosis Progression
New software analysis may help doctors better track how lung disease changes over time.
Updated on Oct. 1, 2026 in Asthma
Live Poll
Do you believe medical imaging technology is effectively making health diagnoses more accurate?
A Phase III study has found that quantitative CT lung measurements, analyzed via the Brainomix e-Lung software, correlate with how pulmonary fibrosis progresses in patients. These findings, published in the American Journal of Respiratory & Critical Care Medicine, could change how specialists evaluate treatment response.
Why it matters
Currently, doctors rely on measures like Forced Vital Capacity (FVC) to monitor disease, but adding quantitative CT metrics may provide a more precise way to stratify patients and assess treatment efficacy in real time. This approach could eventually improve personalized management for those living with progressive pulmonary fibrosis.
In a Phase III study of 474 patients, researchers used the Brainomix e-Lung software to assess quantitative CT measures compared against the UCLA research algorithm. Data showed that higher baseline measurements were associated with a greater rate of FVC decline over 52 weeks.
The players
Brainomix
A medical technology company specializing in AI-powered imaging software for stroke, lung, and heart conditions.
UCLA
A major public research university that develops imaging algorithms used in clinical studies of pulmonary diseases.
Royal Brompton Hospital
A specialist heart and lung hospital that conducts research into pulmonary fibrosis and advanced respiratory care.
The details
The Brainomix e-Lung software works by providing automated, quantitative assessments of CT scans, which detect subtle changes in lung tissue density that standard visual assessment might miss. By measuring the Total Disease Extent, the software helps quantify how much of the lung is affected by fibrosis, allowing clinicians to track the drug Nintedanib's impact on disease progression.
Timeline
24 weeks: Assessment of Nintedanib effects on e-Lung metrics.
52 weeks: Assessment of Nintedanib effects and FVC decline.
Health Landscape
This research follows a pattern set by the INBUILD study in expanding the role of diagnostic imaging beyond basic observation. It marks a shift toward using automated software to standardize disease monitoring in interstitial lung diseases.
If you are managing pulmonary fibrosis, it is worth discussing with your pulmonologist how CT imaging is used to track your specific disease progression. Ask whether supplemental measures, such as quantitative software assessments, might provide more clarity on your treatment response.
The takeaway
Advanced imaging software may soon offer a more detailed picture of how lung disease responds to treatment beyond conventional breathing tests. Speak with your physician about the current role of quantitative CT scans in your care plan to understand all monitoring options available to you.
Further reading
For more on managing respiratory conditions, visit our Asthma section.
Live Poll
Do you believe medical imaging technology is effectively making health diagnoses more accurate?
